Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Update

Plus Therapeutics, Inc. (NASDAQ:PSTV) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 11,356,718 shares, an increase of 54.9% from the December 31st total of 7,332,320 shares. Based on an average trading volume of 15,662,507 shares, the days-to-cover ratio is presently 0.7 days. Currently, 8.2% of the shares of the stock are sold short. Currently, 8.2% of the shares of the stock are sold short. Based on an average trading volume of 15,662,507 shares, the days-to-cover ratio is presently 0.7 days.

Plus Therapeutics Price Performance

Plus Therapeutics stock traded down $0.02 during midday trading on Friday, hitting $0.23. 10,319,404 shares of the company were exchanged, compared to its average volume of 18,136,428. Plus Therapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $2.31. The company’s fifty day moving average price is $0.50 and its 200-day moving average price is $0.54. The company has a market cap of $31.68 million, a PE ratio of -0.12 and a beta of 0.85.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The company had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million. On average, analysts expect that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Zacks Research cut shares of Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Ascendiant Capital Markets dropped their target price on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, November 21st. D. Boral Capital reduced their target price on Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $1.00 price objective (down from $2.00) on shares of Plus Therapeutics in a report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.75.

Institutional Investors Weigh In On Plus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of PSTV. Susquehanna International Group LLP acquired a new position in shares of Plus Therapeutics in the 3rd quarter worth approximately $46,000. Jane Street Group LLC acquired a new position in shares of Plus Therapeutics in the 2nd quarter worth $41,000. Scientech Research LLC acquired a new stake in shares of Plus Therapeutics during the third quarter worth $100,000. Finally, Altium Capital Management LLC acquired a new position in shares of Plus Therapeutics in the 3rd quarter valued at $628,000. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.